Patents by Inventor Ku-Chuan Hsiao
Ku-Chuan Hsiao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8138316Abstract: Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples.Type: GrantFiled: June 10, 2010Date of Patent: March 20, 2012Assignee: IDEXX Laboratories, Inc.Inventors: Philip Andersen, Melissa Jane Beall, Jesse Buch, Ku-chuan Hsiao, Stacey Pazar Huth, Eugene Regis Krah, III, Barbara O'Brien, Marilyn Strong-Townsend
-
Publication number: 20100267131Abstract: Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples.Type: ApplicationFiled: June 10, 2010Publication date: October 21, 2010Applicant: IDEXX LABORATORIES, INC.Inventors: Philip Andersen, Melissa Jane Beall, Jesse Buch, Ku-chuan Hsiao, Stacey Pazar Huth, Eugene Regis Krash, III, Barbara O'Brien, Marilyn Strong-Townsend
-
Patent number: 7771960Abstract: Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples.Type: GrantFiled: October 15, 2008Date of Patent: August 10, 2010Assignee: IDEXX Laboratories, Inc.Inventors: Philip Andersen, Melissa Jane Beall, Jesse Buch, Ku-chuan Hsiao, Stacey Pazar Huth, Eugene Regis, Barbara O'Brien, Marilyn Strong-Townsend
-
Publication number: 20090098576Abstract: Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples.Type: ApplicationFiled: October 15, 2008Publication date: April 16, 2009Applicant: IDEXX Laboratories, Inc.Inventors: Philip Andersen, Melissa Jane Beall, Jesse Buch, Ku-chuan Hsiao, Stacey Pazar Huth, Eugene Regis Krah, Barbara O'Brien, Marilyn Strong-Townsend
-
Publication number: 20090053807Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.Type: ApplicationFiled: December 3, 2007Publication date: February 26, 2009Applicants: Novo Nordisk A/S, Antyra Inc.Inventors: Renuka Pillutla, Olga Dedova, Arthur J. Blume, Neil I. Goldstein, Renee Brissette, Pinger Wang, Hao Liu, Ku-chuan Hsiao, Michael Lennick, Paul Fletcher
-
Patent number: 7173005Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.Type: GrantFiled: September 24, 2002Date of Patent: February 6, 2007Assignees: Antyra Inc., Novo Nordisk A/SInventors: Renuka Pillutla, Olga Dedova, Arthur J. Blume, Neil I. Goldstein, Renee Brissette, Pinger Wang, Hao Liu, Ku-Chuan Hsiao, Michael Lennick, Paul Fletcher
-
Publication number: 20070004634Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.Type: ApplicationFiled: April 24, 2006Publication date: January 4, 2007Applicants: Novo Nordisk A/S, Antyra Inc.Inventors: Renuka Pillutla, Olga Dedova, Arthur Blume, Neil Goldstein, Renee Brissette, Pinger Wang, Hao Liu, Ku-chuan Hsiao, Michael Lennick, Paul Fletcher
-
Publication number: 20040023887Abstract: Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonist peptides may also be developed as therapeutics.Type: ApplicationFiled: September 24, 2002Publication date: February 5, 2004Inventors: Renuka Pillutla, Olga Dedova, Arthur J. Blume, Neil I. Goldstein, Renee Brissette, Pinger Wang, Hao Liu, Ku-Chuan Hsiao, Michael Lennick, Paul Fletcher
-
Publication number: 20030054348Abstract: Methods are disclosed for determining the activity and function of gene products based on their change to the phenotype of cells when contacted with a surrogate molecule identified through screening of a recombinant peptide library. By identifying peptides which bind gene products for which the function is not yet known, tools are provided for determining their function and obtaining drug candidates.Type: ApplicationFiled: May 9, 2001Publication date: March 20, 2003Inventors: Arthur J. Blume, Neil Goldstein, Renuka Pillutla, Ku-Chuan Hsiao, John Prendergast